Form 4 for NVCT Nuvectis Pharma, Inc.
Accepted 2023-05-18 00:00:00 ET · period of report 2023-05-16 · accession 0001104659-23-062078 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-05-18 | 2023-05-16 | NVCT | BENTSUR RON | COB, CEO, Dir, 10% | P - Purchase | $17.03 | +320 | 3.23M | +0.0% | +$5,450 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-05-16 | P | A | 320 | $17.03 | 3,228,649 | D | — | — | (F2) Includes 216,759 shares of restricted stock and 210,000 restricted stock units. (F1) Reflects the weighted average purchase price. The range of prices for the shares purchased was $16.95 to $17.15. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. |